Knoll Mavik once-daily ACE inhibitor will launch in June following April 26 approval.
KNOLL MAVIK ACE INHIBITOR WILL LAUNCH IN JUNE following approval April 26. Mavik (trandolapril) had been "approvable" at FDA since Sept. 25 for the treatment of hypertension. Knoll Pharmaceutical will launch Mavik at 50 [cents] per tablet, according to "coming soon" ads that ran earlier this year ("The Pink Sheet" March 25, T&G-3). Mavik tablets will be priced the same for 1 mg, 2 mg and 4 dosage strengths.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth